Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 23,68 € (+5,57 %). La mediana es de 23,09 € (+2,94 %).
| Comprar |
15 |
| Mantener |
5 |
| Vender |
2 |
Noticias Ir al feed de noticias
Fitch upgrades Elanco after debt reduction and market share gains
Fitch Ratings has raised Elanco’s long-term issuer default rating from BB to BB+ and upgraded the rating on senior secured obligations to BBB-, with a stable outlook. The agency cites successful debt reductions of about $650 million since 2024, market share gains in the pet health segment, a broad product portfolio and improved cash‑flow generation. Fitch expects leverage to fall (gross leverage toward 3.0x by end‑2027), rising free cash flows through 2028 and EBITDA margins of around 21–22% after 2026. In the near term, freed cash flow is expected to be used primarily for debt repayment, while Elanco invests in product expansion, manufacturing and targeted acquisitions. » Más en de.investing.com
Elanco receives FDA emergency approval for wound spray CLiK Extra against screw-worm fly
Elanco has received emergency approval from the FDA for the wound spray CLiK Extra, authorized to prevent infestations by the New World screw-worm fly in livestock and certain wild animals. The topical dicyclanil suspension may be used on sheep, cattle, goats, swine, camelids, captive deer, American bison, bighorn sheep and pronghorn, but it does not treat active infestations. Animals of the listed species must not be slaughtered for human consumption within 86 days after treatment; there is no established milk withdrawal period, and the product must not be used on milk-producing animals for human consumption. CLiK Extra will be available through usual veterinary distribution channels and the approval is valid for the duration of the federal emergency. » Más en de.investing.com
Elanco: study shows Credelio Quattro kills black-legged ticks faster than competitors
Data in Parasites & Vectors show that Credelio Quattro reduces infections with black-legged ticks within 8 hours after treatment, both on day 0 and on day 28 of the dosing interval. Competing products Simparica Trio and NexGard Plus achieved significant reductions only after 12 and 24 hours, respectively, on day 28. Credelio Quattro is FDA-approved for Lyme prevention in dogs; common side effects in studies were vomiting and diarrhea, and the drug class has been linked to neurological effects. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | junio de 2026 | YoY |
|---|---|---|
| Ingresos | 1198,66 M | 13,84 % |
| Beneficio bruto | 699,22 M | 42,83 % |
| Beneficio neto | 47,32 M | 406,99 % |
| EBITDA | 240,08 M | 7,19 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 10,9 mil M € |
Número de acciones | 499,45 M |
Máximo/mínimo de 52 semanas | 24,84 € - 17,23 € |
| Dividendos | No |
Beta | 1,72 |
Ratio P/E | -59,93 |
Ratio PEG | 0,38 |
Ratio P/B | 1,86 |
Ratio P/S | 2,44 |
Perfil de la empresa
Elanco Animal Health Incorporated, una empresa de salud animal, innova, desarrolla, fabrica y comercializa productos para mascotas y animales de granja. Ofrece productos de prevención de enfermedades para la salud de las mascotas, como productos parasiticidas y vacunas que protegen a las mascotas de gusanos, pulgas y garrapatas bajo las marcas Seresto, Advantage, Advantix y Advocate; terapias para la salud de las mascotas destinadas al dolor, la osteoartritis, las infecciones de oído, las indicaciones cardiovasculares y dermatológicas en caninos y felinos bajo las marcas Galliprant y Claro; vacunas, antibióticos, parasiticidas y otros productos para su uso en la producción avícola y acuícola, así como productos de salud nutricional, incluidos enzimas, probióticos y prebióticos; y una gama de vacunas, antibióticos, implantes, parasiticidas y otros productos utilizados en la producción de rumiantes y porcino bajo las marcas Rumensin y Baytril. La empresa vende sus productos a distribuidores externos; veterinarios; y productores de animales de granja, incluidos ganaderos de carne y de leche, así como explotaciones porcinas, avícolas y acuícolas. Elanco Animal Health Incorporated fue fundada en 1954 y tiene su sede en Greenfield, Indiana.
| Nombre | Elanco Animal Health |
| CEO | Jeffrey N. Simmons |
| Sede | Indianapolis,
in Estados Unidos |
| Sitio web | |
| Sector | Salud |
| Industria | Productos farmacéuticos |
| Salida a bolsa | 20/09/2018 |
| Empleados | 9650 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NYSE | ELAN |
Frankfurt | 5EA.F |
Düsseldorf | 5EA.DU |
München | 5EA.MU |